Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Vaccine Strategies in HIV-infected and HIV-uninfected Adults
NCT05515042Phase 2Active, not recruiting
- Sponsor
- Aurum Institute
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Ad26.COV2.S, SARS-CoV-2 rS antigen, tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Aurum Institute. Started Jul 2022; status: active, not recruiting.
02
Drugs
Ad26.COV2.SSARS-CoV-2 rS antigentozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05515042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515042.